目的:比较齐拉西酮与利培酮治疗女性精神分裂症的疗效及安全性.方法:将72例女性精神分裂症患者随机分为齐拉两酮组[(131.6±10.3)mg/d]36例,利培酮组[(5.9±1.3)mg/d]36例,疗程均为12周,采用阳性及阴性症状量表(PANSS),治疗中需处理的不良反应症状量表(TESS),在治疗前及治疗第2、4、8、12周末分别评定疗效和不良反应.结果:治疗第2周末开始,两组PANSS评分较入组时均显著降低,差异有统计学意义(P<0.05);治疗结束时,齐拉西酮组、利培酮组显效率及临床总有效率分别为50.0%、77.8%与47.3%、75.0%,两组疗效比较差异无统计学意义(P>0.05).不良反应的发生率齐拉西酮组为47.2%(17/36)、利培酮组为52.8%(19/36),两组比较,差异无统计学意义(P>0.05).但齐拉西酮组锥体外系反应、体重增加、血脂增高、高泌乳素的发生率明显低于利培酮组,差异有统计学意义(P<0.05).结论:齐拉西酮治疗女性精神分裂症疗效好,不良反应轻微.%Objective: To compare the efficacy and safety of Ziprasidone and Risperidone in the treatment of female patients with schizophrenia.Methods: A total of 72 female patients were randomly assigned to Ziprasidone group (n=36) and Risperidone group (n=36), and received Ziprasidone (131.6±10.3) mg/d and Risperidone (5.9±1.3) mg/d treatment for 12 weeks respectively.The efficacy and adverse reaction were assessed with the Positive and Negative Syndrome Sale (PANSS), the Treatment Emergency Syndrome Scale (TESS) after the tveatment of 2,4, 8, 12 week.Results: The PANSS scores significantly decreased compared with the baseline sores in both groups since the second week (P＜0.05); the marked improvement rate was 50.0％ and the total clinical effective rate was 77.8％ in Ziprasidone group while 47.3％ and 75.0％ in Risperidone group, there were not significant differences between two groups (P＞0.05).There were similar rates of side effects between both groups (P＞0.05), Ziprasidone group was 47.2％ (17/36) and Risperidone group was 52.8％ (19/36) (P＞0.05).But the incidence of extrapyramidal symptoms, weight gain, high blood fat, hyperprolactin were significantly lower in the Ziprasidone group than those in the Risperidone group (P＜0.05).Conclusion: The results suggest Ziprasidone be of good efficacy and less adverse effects in the treatment of female patiens with schizophrenia.
展开▼
